

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: L. SHAPIRO

Application No.: 09/518,081 /

Group Art Unit: 1652

Filed: March 3, 2000

Examiner: Kathleen Kerr

For:

METHODS AND COMPOSITIONS FOR

Attorney D

Attorney Docket No. 330310.00200

INHIBITING APOPTOSIS USING SERINE PROTEASE INHIBITORS (AS AMENDED)

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated September 25, 2003 (Paper No. 19), and in accordance with the Rules of Practice, please enter the following amendments and consider the remarks below. Submitted herewith is: (a).

01/27/2004 SDENBOB1 00000075 09518081

01 FC:2251

55.00 OP

BECEIVED
JAN 3 0 2004

THE AMENDMENTS

Formalities:

Please change the Attorney Docket No. to "330310.00200."

Information Disclosure Statement:

At Paragraph 4 of Paper No. 19, the Office Action asserts that the information disclosure statement filed on May 4, 2001 (Paper No. 3) has not been considered because the references were not filed for consideration. Applicants are in the process of obtaining copies of the references and will therefore attend to submission of the references in due course.

Formal Drawings:

At Paragraph 5 of Paper No. 19, the Office Action indicates that the formal drawings have not been filed in this application and that the requirement for same will not be held in abeyance, Applicants are submitting concurrently herewith the formal drawings for the above-identified application.

In The Claims:

A marked-up version of the claims that will be pending following entry of the present amendments showing the amendments made herein follows. Matter that has been deleted from the claims is indicated by strikethrough and matter that has been added is indicated by underlining.